View Older Stories View More Recent Stories
-
Ascendis Pharma (ASND) PT Raised to $224 at Oppenheimer
-
TD Cowen Reiterates Top Pick and Buy Rating on Ascendis Pharma (ASND)
-
RBC Capital on Ascendis Pharma (ASND): 'Yorvipath Survey Suggests a Potential Upside To Peak Numbers'
-
Canaccord Genuity Reiterates Hold Rating on Ascendis Pharma (ASND)
-
Wells Fargo Reiterates Overweight Rating on Ascendis Pharma (ASND)
-
Ascendis Pharma (ASND) PT Raised to $216 at BofA Securities
-
Ascendis Pharma (ASND) PT Raised to $201 at BofA Securities
-
Ascendis Pharma (ASND) Announces FDA Acceptance of TransCon CNP NDA for Priority Review
-
Stifel Reiterates Buy Rating on Ascendis Pharma (ASND)
-
Biotech stocks Q1 earnings review
-
Cerrado Gold and Ascendant Resources Announce Completion of Business Combination Transaction
-
Cerrado Gold and Ascendant Resources Announce Completion of Business Combination Transaction
-
Ascendis Pharma (ASND) : New Data Shows Improvements in Growth and Bone Morphometry in Children with Achondroplasia Treated with TransCon CN
-
Ascendis Pharma (ASND): New 4-Year Data Shows Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism
-
Cantor Fitzgerald Reiterates Overweight Rating on Ascendis Pharma (ASND)
-
Morgan Stanley Upgrades Ascendis Pharma (ASND) to Overweight
-
Ascendis Pharma (ASND) PT Raised to $245 at JPMorgan
-
Ascendis Pharma (ASND) PT Raised to $280 at Evercore ISI, 'remains a top pick'
-
Ascendis Pharma (ASND) Misses Q1 EPS by 11c
-
RBC Capital Starts Ascendis Pharma (ASND) at Outperform
-
Smid cap biotech investors must stop chasing binary events says Cantor Fitzgerald
-
Ascendis Pharma (ASND) Submits U.S. NDA for TransCon CNP for the Treatment of Children with Achondroplasia
-
UBS Reiterates Buy Rating on Ascendis Pharma (ASND)
-
Cantor Fitzgerald says 15% of biotech companies down 40% or more
-
Bernstein provides 2025 M&A outlook for U.S. Biotech and Pharma
-
Ascendis Pharma (ASND) PT Raised to $200 at Cantor Fitzgerald
-
Ascendis Pharma (ASND) PT Raised to $260 at Evercore ISI, Top Pick
-
Biotech Q4 earnings preview: Goldman Sachs
-
Ascendis Pharma (ASND) PT Raised to $162 at TD Cowen; 'Yorvipath Off to Solid Launch'
-
Ascendis Pharma (ASND) PT Raised to $212 at Stifel
-
Ascendis Pharma (ASND) PT Raised to $225 at Goldman Sachs
-
Ascendis Pharma (ASND) announces $25 million share repurchase program
-
Cantor Fitzgerald Reiterates Overweight Rating on Ascendis Pharma (ASND)
-
Ascendis Pharma (ASND) PT Raised to $167 at JPMorgan
-
Goldman Sachs Reiterates Buy Rating on Ascendis Pharma (ASND)
-
BioMarin Pharma (BMRN) Announces Legal Action Against Ascendis Pharma A/S in European Unified Patent Court
-
UBS Starts Ascendis Pharma (ASND) at Buy
-
Ascendis Pharma (ASND) PT Raised to $194 at Jefferies
-
Ascendis Pharma (ASND): FDA Accepts SBLA for TransCon hGH for the Treatment of Adults with Growth Hormone Deficiency
-
Ascendis Pharma (ASND) Selects PANTHERx Rare for the Distribution of YORVIPATH® (palopegteriparatide)
-
Ascendis Pharma (ASND) PT Lowered to $153 at TD Cowen
-
Ascendis Pharma (ASND) PT Lowered to $200 at Citi
-
Ascendis Pharma (ASND) PT Lowered to $180 at Oppenheimer
-
Ascendis Pharma (ASND) Misses Q3 EPS by 18c, provides outlook
-
Ascendis Pharma (ASND) and Novo Nordisk (NVO) Sign Collaboration for Development and Commercialization of TransCon Technology-based Products in Metabolic and Cardiovascular Diseases
-
Ascendis Pharma (ASND) PT Raised to $160 at TD Cowen
-
Ascendis Pharma (ASND) Announces Submission of Supplemental Biologics License Application to FDA for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency
-
Ascendis Pharma (ASND): New 3-Year Skeletal Dynamics Data for Adults with Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide) Presented at ASBMR 2024
-
BofA Securities Reiterates Buy Rating on Ascendis Pharma (ASND)
-
Ascendis Pharma (ASND) Prices 2M Share Offering at $150/sh
